Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
McKesson
Fish and Richardson
Merck
Argus Health
Chubb
US Department of Justice
Boehringer Ingelheim
Cantor Fitzgerald

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FOSAPREPITANT DIMEGLUMINE

« Back to Dashboard

Clinical Trials for FOSAPREPITANT DIMEGLUMINE

Trial ID Title Status Sponsor Phase Summary
NCT00818259 A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) Terminated Merck Sharp & Dohme Corp. Phase 1 This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
NCT00895245 Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
NCT00895245 Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy Terminated University of Washington Phase 2 RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
NCT00945321 A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) Completed Merck Sharp & Dohme Corp. Phase 1 This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
NCT01031953 Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy Terminated National Cancer Institute (NCI) Phase 1/Phase 2 RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.
NCT01031953 Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy Terminated OHSU Knight Cancer Institute Phase 1/Phase 2 RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for FOSAPREPITANT DIMEGLUMINE

Condition Name

Condition Name for FOSAPREPITANT DIMEGLUMINE
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 4
Nausea 2
Vomiting 2
Unspecified Adult Solid Tumor, Protocol Specific 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for FOSAPREPITANT DIMEGLUMINE
Intervention Trials
Vomiting 11
Nausea 7
Neoplasms 1
Nasopharyngeal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for FOSAPREPITANT DIMEGLUMINE

Trials by Country

Trials by Country for FOSAPREPITANT DIMEGLUMINE
Location Trials
United States 6
Germany 1
Denmark 1
Australia 1
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for FOSAPREPITANT DIMEGLUMINE
Location Trials
Massachusetts 1
California 1
Michigan 1
Texas 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for FOSAPREPITANT DIMEGLUMINE

Clinical Trial Phase

Clinical Trial Phase for FOSAPREPITANT DIMEGLUMINE
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for FOSAPREPITANT DIMEGLUMINE
Clinical Trial Phase Trials
Completed 5
Terminated 3
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for FOSAPREPITANT DIMEGLUMINE

Sponsor Name

Sponsor Name for FOSAPREPITANT DIMEGLUMINE
Sponsor Trials
National Cancer Institute (NCI) 5
Merck Sharp & Dohme Corp. 5
M.D. Anderson Cancer Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for FOSAPREPITANT DIMEGLUMINE
Sponsor Trials
Other 7
Industry 6
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Argus Health
US Department of Justice
Queensland Health
Boehringer Ingelheim
Moodys
QuintilesIMS
Accenture
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.